Pharma News

Sun Pharma and and Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing essential dermatological conditions today announced the signing of License and Supply Agreements for Winlevi (clascoterone cream 1%) in the United States and Canada. Winlevi  has been approved by the United States Food and Drug Administration FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of the Percept PC Deep Brain Stimulation system. The system enabled with BrainSense technology is designed to capture brain signals while simultaneously delivering therapeutic stimulation, inside and outside the clinic. Ergonomically designed, the Percept PC device offers enhanced comfort and is indicated for patients with Parkinson’s disease, tremor, dystonia, and epilepsy.

A national research study has just launched to investigate the effectiveness and safety of COVID-19 vaccines in transplant recipients. The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing over $2.84 million in this research study, based at University Health Network and called PREVenT COVID, short for Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients : A National Strategy.

Human brain is one of the most powerful and intelligent natural computer known to mankind. Neuromorphic computing refers to the field of technology where engineers try to build intelligent machines inspired from the working of mammal brains. Neurons and synapses are believed to be the most important building blocks giving rise to intelligence inside brains.

Roche announced that Venclexta in combination with azacitidine has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System . MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells. This can lead to weakness, frequent infections, anaemia and debilitating fatigue.

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA te

Roche announced that Japans Ministry of Health, Labour and Welfare has approved Ronapreve  casirivimab and imdevimab, for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act.

Integra Life Sciences Holding Corporation a leading global medical technology company announced positive clinical outcomes for PriMatrix Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers. This study is one of the largest DFU randomized controlled trials ever completed with more than 100 patients per treatment group and demonstrated that in most cases, one application of PriMatrix plus standard of care healed 60% of DFUs in 12 weeks versus 35% of DFUs that healed in 12 weeks with SOC for the per protocol analysis.

PLx Pharma Inc a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products, with its lead products VAZALORE 325 mg and VAZALORE 81 mg ,referred to together as VAZALORE, announced that three stock-keeping units of VAZALORE, the first and only U.S. Food and Drug Administration approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.